CClinicalTrials.gg
CompletedNCT02232711Updated Jul 24, 2015

Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting

An observational study in Upper Respiratory Infections, sponsored by BioFire Diagnostics, LLC. Completed at 4 sites in United States. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by BioFire Diagnostics, LLC · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,082
Sex
All
01

Study summary

The purpose of this study is to assess the accuracy and ease-of-use of a simplified FilmArray Respiratory Panel test (FilmArray RP EZ) when performed according to the manufacturer's instructions by personnel in laboratories holding Clinical Laboratory Improvement Amendments (CLIA) waivers (or equivalent) on nasopharyngeal swab samples obtained from volunteers with signs and/or symptoms of a respiratory infection. The study data will be used to support an application to the FDA for CLIA-waived categorization of FilmArray RP EZ. It is hypothesized that the results of the FilmArray RP EZ test performed in a laboratory with CLIA waiver with be 95% accurate when compared to FilmArray RP testing performed in a lab with a moderate or high complexity CLIA certification.

02

Conditions studied

  • Upper Respiratory Infections

Keywords

  • multiplex, polymerase chain reaction, PCR, BioFire, respiratory infection, infectious disease, point of care, CLIA waived, rapid diagnostics
03

In context

Respiratory Tract Infections

1,031 studies on the registry are indexed under Respiratory Tract Infections; 144 are open to participants now.

This study's enrollment of 1,082 is above the median of 300 across 295 observational studies indexed under Respiratory Tract Infections.

Browse Respiratory Tract Infections studies →

Lead sponsor

BioFire Diagnostics, LLC is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with signs and/or symptoms of respiratory infections

Inclusion criteria

  • Displays signs and/or symptoms of respiratory infections
  • Adult patients must provide informed consent
  • Parental consent for children (\<18)

Exclusion criteria

Exclusion Criteria:

  • Adult patients unable to provide informed consent
  • Children that are currently in foster care, or are wards of the state
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,082 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Accuracy of FilmArray RP EZ System in detecting cause of respiratory illness

    In general, performance of the FilmArray RP EZ test in the CLIA-waived setting is expected to meet at least 95% positive and negative percent agreement with the results obtained from FilmArray RP in the moderate/high- complexity setting for each pathogen on the panel.

    Time frame: 1.5 hour

Secondary outcomes

  1. Epidemiology of respiratory infections in a CLIA-waived setting

    Seasonality and rate of respiratory infection at each of the CLIA-waived sites using the FilmArray RP EZ to collect prospectively enrolled specimens will be evaluated at the end of the study.

    Time frame: Up to 9 months

07

Study locations

4 sites
  • Naval Health Research Center
    San Diego, California 92152, United States
  • Barnes-Jewish/Washington University School of Medicine
    St. Louis, Missouri 63103, United States
  • UTMB Primary Care Pavilion
    Galveston, Texas 77550, United States
  • South Main Clinic
    Salt Lake City, Utah 84115, United States
08

References and documents

Publications

  • Barenfanger J, Drake C, Leon N, Mueller T, Troutt T. Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study. J Clin Microbiol. 2000 Aug;38(8):2824-8. doi: 10.1128/JCM.38.8.2824-2828.2000. PubMed 10921934 ↗
  • Buller RS. Molecular detection of respiratory viruses. Clin Lab Med. 2013 Sep;33(3):439-60. doi: 10.1016/j.cll.2013.03.007. PubMed 23931834 ↗
  • Fairfax MR, Salimnia H. Diagnostic molecular microbiology: a 2013 snapshot. Clin Lab Med. 2013 Dec;33(4):787-803. doi: 10.1016/j.cll.2013.08.003. PubMed 24267186 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02232711
Lead sponsor
BioFire Diagnostics, LLC
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Sep 5, 2014
Start date
Nov 2014
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Jul 24, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion